8-K: Kiromic BioPharma Secures $2 Million in Funding Through Convertible Note

Kiromic BioPharma has entered into a $2 million financing agreement by issuing a senior secured convertible promissory note to an accredited investor.

Summary

• Kiromic BioPharma issued a 25% Senior Secured Convertible Promissory Note for $2 million to an accredited investor on December 9, 2024.
• The note has a 25% annual interest rate, maturing on December 9, 2025, with the rate increasing to 27% upon default.
• The holder can convert the note into common stock starting January 31, 2025, at 90% of the 5-day VWAP before the conversion notice.
• The note is secured by the company's fixtures, equipment, and intellectual property.
• The holder now has a total of $13.2 million in outstanding promissory notes, along with various series of convertible preferred stock.

Sentiment

Score: 4

Explanation: The high interest rate and secured nature of the debt indicate a higher risk profile for the company, despite the successful capital raise. The potential for equity dilution is also a concern.

Positives

• The company has successfully secured $2 million in funding.
• The convertible note provides a potential future equity conversion for the investor.
• The company retains the option to prepay the note without penalty.

Negatives

• The 25% interest rate on the note is very high.
• The interest rate increases to 27% upon default, adding further financial pressure.
• The note is secured by the company's assets, potentially limiting future financing options.
• The conversion price is based on a 5-day VWAP, which could be volatile.

Risks

• The high interest rate of 25% could strain the company's finances.
• Failure to meet payment obligations could trigger a default and increase the interest rate to 27%.
• The company's assets are pledged as collateral, which could be at risk in case of default.
• The conversion of the note could dilute existing shareholders.

Future Outlook

The company intends to use the proceeds for the continued development of its CAR-T cell therapy and for general corporate purposes.

Management Comments

• The company has not provided any direct quotes in this document.

Industry Context

This financing is typical for a biotech company in the development stage, seeking capital to fund research and development. The use of a convertible note is a common method for raising funds, offering investors potential upside through equity conversion.

Comparison to Industry Standards

• The 25% interest rate is significantly higher than typical rates for secured debt, suggesting the company may have limited access to traditional financing.
• Convertible notes are a common financing tool for early-stage biotech companies, but the specific terms, such as the high interest rate and the conversion discount, are specific to the company's situation and risk profile.
• Comparable companies in the biotech sector often use a mix of equity and debt financing, with the terms of each deal varying based on the company's stage, risk, and market conditions.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted to equity.
• Employees may benefit from the continued funding of the company's operations.
• Creditors may be impacted by the senior secured nature of the note.

Next Steps

• The company will use the funds for continued development of its CAR-T cell therapy and general corporate purposes.
• The company is required to file a registration statement for the resale of the conversion shares within 30 days of the Conversion Share Delivery Date.

Key Dates

Keywords

convertible note, financing, promissory note, secured debt, biopharma, investment, equity conversion, debt financing, capital raise